Somaiah, N., Conley, A. P., Parra, E. R., Lin, H., Amini, B., Solis Soto, L., Salazar, R., Barreto, C., Chen, H., Gite, S., Haymaker, C., Nassif, E. F., Bernatchez, C., Mitra, A., Livingston, J. A., Ravi, V., Araujo, D. M., Benjamin, R., Patel, S., Zarzour, M. A., Sabir, S., Lazar, A. J., Wang, W., Daw, N. C., Zhou, X., Roland, C. L., Cooper, Z. A., Rodriguez-Canales, J., Futreal, A., Soria, J., Wistuba, I. I., & Hwu, P. (2022). durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet oncology, 23(9), 1156–1166. http://access.bl.uk/ark:/81055/vdc_100164416445.0x00001a